Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

In his witness statement, Professor Ludlam accepted that cryoprecipitate had transformed the treatment of patients with Haemophilia A and allowed most bleeds in non-inhibitor patients to be treated effectively.

  • Read more about In his witness statement, Professor Ludlam accepted that cryoprecipitate had transformed the treatment of patients with Haemophilia A and allowed most bleeds in non-inhibitor patients to be treated effectively.

In a letter to John Watt, it was stated that Dr Ludlam planned to start an active home therapy programme for some of his haemophilic patients.

  • Read more about In a letter to John Watt, it was stated that Dr Ludlam planned to start an active home therapy programme for some of his haemophilic patients.

Dr Kernoff wrote to patients explaining that it would not be possible to change everybody to heat-treated products immediately. The overall objective of the Royal Free's policy was said to be to give the safest possible treatment to an individual.

  • Read more about Dr Kernoff wrote to patients explaining that it would not be possible to change everybody to heat-treated products immediately. The overall objective of the Royal Free's policy was said to be to give the safest possible treatment to an individual.

The Royal Free's annual return for 1984 showed that commercial concentrates remained the principal treatment for Haemophilia A, although the volume of NHS concentrates increased.

  • Read more about The Royal Free's annual return for 1984 showed that commercial concentrates remained the principal treatment for Haemophilia A, although the volume of NHS concentrates increased.

The Royal Free's annual return for 1983 showed that commercial concentrates remained the principal treatment for Haemophilia A.

  • Read more about The Royal Free's annual return for 1983 showed that commercial concentrates remained the principal treatment for Haemophilia A.

NETR Haemophilia Working Party agreed to use heat-treated material whenever possible and to treat all new patients and those with mild haemophilia with heat-treated NHS concentrate or small pool Factor 8 concentrate if treatment with cryoprecipitate or DDAVP was not possible.

  • Read more about NETR Haemophilia Working Party agreed to use heat-treated material whenever possible and to treat all new patients and those with mild haemophilia with heat-treated NHS concentrate or small pool Factor 8 concentrate if treatment with cryoprecipitate or DDAVP was not possible.

Professor Lee confirmed that no changes were made in the Royal Free's treatment policies until heat-treated products became available at the end of 1984

  • Read more about Professor Lee confirmed that no changes were made in the Royal Free's treatment policies until heat-treated products became available at the end of 1984

Professor Bloom told the audience at a Haemophilia Society meeting that one of his patients "may have a mild form" of the syndrome.

  • Read more about Professor Bloom told the audience at a Haemophilia Society meeting that one of his patients "may have a mild form" of the syndrome.

The West Midlands Working Party held an extraordinary meeting to discuss the implications of the use of Factor 8 concentrates in light of the death of two people with haemophilia from AIDS and a treatment policy was agreed

  • Read more about The West Midlands Working Party held an extraordinary meeting to discuss the implications of the use of Factor 8 concentrates in light of the death of two people with haemophilia from AIDS and a treatment policy was agreed

Professor Franklin wrote to Dr Lane registering his concern about the shortfall, which meant that the Centre might have to treat patients with commercial product who had never been exposed to it in the past.

  • Read more about Professor Franklin wrote to Dr Lane registering his concern about the shortfall, which meant that the Centre might have to treat patients with commercial product who had never been exposed to it in the past.

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 37
  • Page 38
  • Page 39
  • Page 40
  • Current page 41
  • Page 42
  • Page 43
  • Page 44
  • Page 45
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.